Abstract
BackgroundPatients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR). To date, no predictable biomarker can be applied in the clinic. MicroRNAs (miRNAs or miRs) play critical roles in transcription regulation, and their circulating levels were reported to have potential as clinical biomarkers.MethodsIn total, 93 coronary stent-implanted patients without pregnancy, liver or renal dysfunction, malignancy, hemophilia, or autoimmune diseases were recruited in this clinical study. All recruited participants were divided into an ISR group (n = 45) and a non-ISR group (n = 48) based on their restenotic status as confirmed by cardiologists at the first follow-up visit (6 months after surgery). Blood samples of all participants were harvested to measure circulating levels of miRNA candidates (miR-132, miR-142-5p, miR-15b, miR-24-2, and miR-424) to evaluate whether these circulating miRNAs can be applied as predictive biomarkers of ISR.ResultsOur data indicated that circulating levels of miR-142-5p were significantly higher in the ISR population, and results from the receiver operating characteristic (ROC) curve analysis also demonstrated superior discriminatory ability of miR-142-5p in predicting patients’ restenotic status. In addition, circulating levels of miR-15b, miR-24-2, and miR-424 had differential expressions in participants with diabetes, hyperlipidemia, and hypertension, respectively.ConclusionsThe current study revealed that the circulating level of miR-142-5p has potential application as a clinical biomarker for predicting the development of ISR in stent-implanted patients.
Highlights
Patients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR)
Circulating levels of miRNA candidates To compare the difference in expressions of each miRNA, we performed a Quantitative polymerase chain reaction (qPCR) to measure relative levels of circulating miRNAs of the ISR group compared to the nonISR group
Predictable biomarkers of ISR could be clinically applied for reducing wasteful practices by helping us to distinguish precisely who belongs to the susceptible population and the most suitable intervention could be chosen for individual patients
Summary
Patients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR). MicroRNAs (miRNAs or miRs) play critical roles in transcription regulation, and their circulating levels were reported to have potential as clinical biomarkers. Restenosis after a percutaneous coronary intervention (PCI) has historically been described as an “Achilles heel” [1]. MiRNAs could be the best fit to investigate the complex restenosis pathology with their disease-specific and ideal-biomarker characteristics. The objective of this study was to clarify correlations of circulating levels of five miRNAs and the prevalence of in-stent restenosis (ISR) in patients who had received vascular stent implantation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
